CDNAS coding for members of the carcinoembryonic antigen family
    2.
    发明授权
    CDNAS coding for members of the carcinoembryonic antigen family 失效
    癌细胞抗原家族成员的CDNAS编码

    公开(公告)号:US5231009A

    公开(公告)日:1993-07-27

    申请号:US760031

    申请日:1991-09-13

    摘要: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

    摘要翻译: 一种核酸,其包含编码CEA家族成员肽序列的碱基序列或具有与其可杂交的碱基序列的核酸,具有包含该核酸的插入片段的可复制重组克隆载体,用该克隆载体转染,感染或注射的细胞,多肽 由这样的细胞表达,衍生自CEA家族成员核酸的编码序列的合成肽,对这些多肽具有特异性的抗体制剂,使用这种抗体制剂检测CEA家族成员的免疫测定法和用于检测CEA家族成员核酸序列的核酸杂交方法,其使用 包含上述核酸的核酸探针。

    cDNAs coding for members of the carcinoembryonic antigen family
    3.
    发明授权
    cDNAs coding for members of the carcinoembryonic antigen family 失效
    编码癌胚抗原家族成员的cDNA

    公开(公告)号:US06342583B1

    公开(公告)日:2002-01-29

    申请号:US08027974

    申请日:1993-03-08

    IPC分类号: C07K1400

    摘要: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

    摘要翻译: 一种核酸,其包含编码CEA家族成员肽序列的碱基序列或具有与其可杂交的碱基序列的核酸,具有包含该核酸的插入片段的可复制重组克隆载体,用该克隆载体转染,感染或注射的细胞,多肽 由这样的细胞表达,衍生自CEA家族成员核酸的编码序列的合成肽,对这些多肽具有特异性的抗体制剂,使用这种抗体制剂检测CEA家族成员的免疫测定法和用于检测CEA家族成员核酸序列的核酸杂交方法,其使用 包含上述核酸的核酸探针。

    CDNA coding for carcinoembryonic antigen
    7.
    发明授权
    CDNA coding for carcinoembryonic antigen 失效
    CDNA编码癌胚抗原

    公开(公告)号:US5843761A

    公开(公告)日:1998-12-01

    申请号:US469987

    申请日:1995-06-06

    摘要: A nucleic acid comprising a base sequence which codes for a CEA peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or infected with such cloning vehicles, polypeptides expressed by such cells, antibody preparations specific for such polypeptides, immunoassays for detecting CEA using such antibody preparations and nucleic acid hybridization methods for detecting a CEA nucleic acid sequence using a nucleic acid probe comprising the above described nucleic acid.

    摘要翻译: 一种核酸,其包含编码CEA肽序列的碱基序列或具有与其可杂交的碱基序列的核酸,具有包含该核酸的插入片段的可复制重组克隆载体,用该克隆载体转染,感染或感染的细胞,由 这样的细胞,对这些多肽有特异性的抗体制剂,使用这种抗体制剂检测CEA的免疫测定法和使用包含上述核酸的核酸探针检测CEA核酸序列的核酸杂交方法。

    Monitoring of NC 50/90 in blood samples of breast cancer patients
    9.
    发明授权
    Monitoring of NC 50/90 in blood samples of breast cancer patients 失效
    监测乳腺癌患者血液中的NC 50/90

    公开(公告)号:US5593847A

    公开(公告)日:1997-01-14

    申请号:US170141

    申请日:1993-12-20

    摘要: A method for aiding in the diagnosis of, and monitoring the progression of, breast cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g. serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of breast cancer in the patient. The progression of breast cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.

    摘要翻译: 一种通过测量血液样品中的NCA 50/90的量来辅助诊断和监测患者乳腺癌的进展的方法,例如, 血清样品,从患者获得。 在单个样品中测量NCA 50/90的量显着高于正常人群中NCA 50/90的平均量,这是患者乳腺癌的指征。 乳腺癌的进展也可以通过随时间进行一系列特异性免疫测定来监测血液样品中NCA 50/90水平的变化。 随着时间的推移,血液NCA 50/90水平的升高表明病情恶化,而随着时间的推移,血液NCA 50/90的水平降低表明改善状况。